ライフサイエンスコーパス: cobra

1 hod of combined bisulfite restriction assay (COBRA).

2 by combined bisulfite restriction analysis (COBRA).

3 or combined bisulfite restriction analysis (COBRA).

4 tionally optimized broadly reactive antigen (COBRA).

5 ay [combined bisulfite restriction analysis (COBRA)].

6 us and can be quantitatively monitored by SB-COBRA.

7 with some of them being easily detectible by COBRA.

8 Here, we describe Bio-COBRA, a modified protocol for Combined Bisulfite Restri

9 erformed a screen for genetic suppressors of cobra, an Arabidopsis mutant with defects in cellulose f

10 peptides (9), fasciclin-like proteins (20), COBRA and 10 homologs, and novel potential signaling pep

11 We next studied 53 patients by COBRA and demonstrated that 72% of patient samples with

12 primers for bisulfite-PCRs (MSP, sequencing, COBRA and multiplex-MSP), allowing the determination of

13 tors of cellulose synthesis, suggesting that COBRA and the cellulose synthase complex reside in close

14 e a novel Computational Brewing Application (COBRA) and apply it to modeling oligomerization chemistr

15 Combined Bisulfite Restriction Analysis (COBRA) and bisulfite sequencing analysis revealed that t

16 and combined bisulfite restriction analysis (COBRA), and quantitative SB-COBRA was performed to study

17 Using the COBRA approach, a set of vaccines against influenza viru

18 We recently identified COB (COBRA) as a key regulator of the orientation of cell exp

19 The Bio-COBRA assay can be performed on 12 samples in less than

20 This is the first report describing a COBRA-based HA vaccine strategy that elicits a broadly r

21 This is the first report describing a COBRA-based HA vaccine strategy that elicits a universal

22 rt the development and characterization of a COBRA-based vaccine for both seasonal and pandemic H1N1

23 Competition assays suggests that COBRA binds individual beta1-4-linked glucan chains with

24 In contrast to properdin, both gCs bound to cobra C3; this finding suggests that gC-1 and properdin

25 ntology and Open Biology Ontologies formats, COBrA can import and export ontologies in the Semantic W

26 In addition, several COBRA candidates were designed based on sequences of H1N

27 Nine HA COBRA candidates were developed, and these vaccines were

28 Cobra cardiotoxins (CTX) are a family of three-fingered

29 onsistent with their ability to suppress the cobra cellulose deficiency.

30 Cynomolgus macaques vaccinated with COBRA clade 2 HA H5N1 virus-like particles (VLPs) had he

31 The COBRA clade 2 HA H5N1 VLP elicits broad humoral immunity

32 Mutations in the COBRA (COB) gene of Arabidopsis, known to affect the ori

33 abidopsis (Arabidopsis thaliana) root is the COBRA (COB) gene that belongs to a multigene family.

34 COBRA (COB) has been identified previously as a potentia

35 ts with severe asthma as comparative groups (COBRA cohort [Cohorte Obstruction Bronchique et Asthme;

36 ng from the Comorbidity in Relation to AIDS (COBRA) cohort.

37 In this report, we describe Bio-COBRA (combined bisulfite restriction analysis coupled w

38 mples are presented where the performance of COBRA, DyMMM and DFBAlab are compared.

39 et the available evidence as suggesting that COBRA facilitates cellulose crystallization from the eme

40 Onstraint Based Reconstruction and Analysis (COBRA) flux prediction algorithms fail.

41 roadly reactive hemagglutinin (HA) antigens (COBRA) for H1N1 isolates.

42 onstraint-based reconstruction and analysis (COBRA) framework has been widely used to study steady-st

43 Mutations in the Arabidopsis COBRA gene lead to defects in cellulose synthesis but th

44 We compare the python and king cobra genomes along with genomic samples from other snak

45 ntibodies induced by wild-type H1N1 viruses, COBRA HA antigens elicited sera with the broadest HAI re

46 fected with influenza viruses expressing the COBRA HA antigens.

47 ferrets with COBRA HA based viruses or using COBRA HA based vaccines to boost preexisting antibodies

48 Overall, priming naive ferrets with COBRA HA based viruses or using COBRA HA based vaccines

49 The top leading COBRA HA candidates were tested against cocirculating va

50 This COBRA HA elicited a broad antibody response against H5N1

51 Four of the 9 H1N1 COBRA HA proteins (X1, X3, X6, and P1) had the broadest

52 irus-like particle (VLP) vaccines expressing COBRA HA proteins elicited antibodies with hemagglutinat

53 Nine prototype H1N1 COBRA HA proteins were developed and tested in mice usin

54 nt and characterization of 17 prototype H3N2 COBRA HA proteins were screened in mice and ferrets for

55 The T-11 COBRA HA vaccine elicited antibodies with HAI and neutra

56 The most effective COBRA HA vaccine regimens elicited antibodies with broad

57 rus and vaccinated with a single dose of the COBRA HA VLP vaccines elicited antibodies with HAI activ

58 eadth of HAI activity after vaccination with COBRA HA VLP vaccines than COBRA preimmune ferrets vacci

59 ing combined bisulfite restriction analysis (COBRA), hypermethylation of this fragment was detected i

60 e imposition of loop-law constraints with ll-COBRA improves the consistency of simulation results wit

61 COBrA is a Java-based ontology editor for bio-ontologies

62 Although the king cobra is limbless, we recovered coding sequences for all

63 COBRA is not limited to atmospheric aerosol chemistry; i

64 s in cellulose synthesis but the function of COBRA is unknown.

65 onstraint-Based Reconstruction and Analysis (COBRA) is currently the only methodology that permits in

66 of the glycosylphosphatidylinositol-anchored COBRA-LIKE gene family in Arabidopsis (Arabidopsis thali

67 andidate gene approach and found to encode a COBRA-like protein similar to rice (Oryza sativa) BC1 an

68 n patterns for transcripts of genes encoding COBRA-like proteins and other cell wall metabolism-relat

69 he course of seed development, we identified COBRA-LIKE2 (COBL2), a member of the glycosylphosphatidy

70 ) BC1 and Arabidopsis (Arabidopsis thaliana) COBRA-LIKE4.

71 integer programming approach called loopless COBRA (ll-COBRA), which can be used to eliminate all ste

72 Here we present evidence that COBRA localizes to discrete particles in the plasma memb

73 The sensitivity and reproducibility of Bio-COBRA make it a valuable tool for the analysis of DNA me

74 One shortcoming of current COBRA methods is the possible violation of the loop law

75 ysis (McCOBRA), which adapt standard MSP and COBRA methods to a melting curve analysis based platform

76 d provides an additional constraint for many COBRA methods, enabling the acquisition of more realisti

77 A Toolbox, a MATLAB package for implementing COBRA methods, was presented earlier.

78 lowers the barrier of entry to use powerful COBRA methods.

79 to improve flux predictions on three common COBRA methods: flux balance analysis, flux variability a

80 onstraint-based reconstruction and analysis (COBRA) methods at the genome scale have been under devel

81 onstraint-based reconstruction and analysis (COBRA) methods to simulate, analyze and predict a variet

82 ic resonance studies of the cell wall of the cobra mutant also indicated that, in addition to decreas

83 ynthesis appeared to proceed normally in the cobra mutant.

84 When separated from the cobra mutation, mutations in MED16 caused resistance to

85 by combined bisulfite restriction analysis (COBRA); mutation of K-ras, p53, p16, and p14 genes by se

86 holipase A2 (PLA2) from the venom of Chinese cobra (Naja naja atra) has high activity on zwitterionic

87 diameter) are exposed to PLA2 isolated from cobra (Naja naja naja) venom at varying enzyme concentra

88 Diabetics With Peripheral Vascular Disease [COBRA]; NCT00827853).

89 ted the genome of a venomous snake, the king cobra (Ophiophagus hannah), and compared it, together wi

90 (mon1) that suppressed the growth defects of cobra, partially restored cellulose levels, and restored

91 opically expressed, partially suppressed the cobra phenotype.

92 These COBRA preimmune ferrets had superior breadth of HAI acti

93 vaccination with COBRA HA VLP vaccines than COBRA preimmune ferrets vaccinated with VLP vaccines exp

94 Bio-COBRA provides a platform for the rapid and quantitative

95 nmethylated from methylated Cytosines (i.e., COBRA, pyrosequencing).

96 d into 5 different families: Supine, Convex, Cobra, Stretch, and Concave motifs.

97 We have used COBRA technology to develop an HA head-based strategy th

98 COBRA technology was effectively used to design HA immun

99 of Hemachatus haemachatus (African Ringhals cobra) that specifically inhibits factor X (FX) activati

100 for Combined Bisulfite Restriction Analysis (COBRA), that incorporates an electrophoresis step in mic

101 COBRA thus combines the powerful features of ease of use

102 port here on a quantitative technique called COBRA to determine DNA methylation levels at specific ge

103 e apply a Computational Brewing Application (COBRA) to simulate the oxidation of squalene in the pres

104 Version 2.0 of the COBRA Toolbox expands the scope of computations by inclu

105 As with the first version, the COBRA Toolbox reads and writes systems biology markup la

106 The COBRA Toolbox, a MATLAB package for implementing COBRA m

107 t for compatibility with old versions of the COBRA toolbox.

108 of a combination treatment in early RA (the COBRA trial), and 1 placebo-controlled trial of a new de

109 COBRA uses two lists as input: a list of chemical struct

110 Therefore, the COBRA vaccines have the ability to elicit protective ant

111 Three of the H3N2 COBRA vaccines recognized all of the cocirculating strai

112 Cobra venom (Naja kaouthia) contains a toxin called alph

113 Phospholipase A2 from cobra venom (Naja naja atra) hydrolyzes carbonothioate p

114 xchange mass spectrometric evaluation of the cobra venom (Naja naja naja) group IA phospholipase A 2

115 Rats given cobra venom factor (CoF) followed by a NTS shown to be c

116 epleting complement in chinchillas by use of cobra venom factor (CoVF) rendered two otherwise avirule

117 Cobra venom factor (CoVF) treatment, which depletes C3 a

118 562 alone (HAR model) or in combination with cobra venom factor (CVF) (DXR model).

119 r first hamster hearts had been surviving in cobra venom factor (CVF) + CyA-treated rats for 10 days,

120 administered the complement-depleting agent cobra venom factor (CVF) 24 hr before HI lesioning and e

121 nografts, the inhibition of complement using cobra venom factor (CVF) accelerates pulmonary xenograft

122 the graft aorta in combination with systemic cobra venom factor (CVF) administration to deplete compl

123 prevented by brief complement inhibition by cobra venom factor (CVF) and sustained T-cell immunosupp

124 Surprisingly, injection of cobra venom factor (CVF) caused a profound and reproduci

125 Cobra venom factor (CVF) depletes complement and may the

126 anted heterotopically into rats treated with cobra venom factor (CVF) develop disease over 72 hours.

127 me of primary immunization by treatment with cobra venom factor (CVF) diminished serum anti-PPS14 con

128 dy sought to (i) investigate the efficacy of cobra venom factor (CVF) in preventing hyperacute reject

129 Cobra venom factor (CVF) induces lung injury through oxi

130 activation of complement by i.v. infusion of cobra venom factor (CVF) is known to be P-selectin depen

131 in vivo, because complement depletion using cobra venom factor (CVF) markedly reduced the efficacy o

132 y after systemic activation of complement by cobra venom factor (CVF) or after intrapulmonary deposit

133 or inhibited by intraperitoneal injection of cobra venom factor (CVF) or complement receptor-related

134 enografts was achieved using either CsA plus cobra venom factor (CVF) or CsA plus rapamycin.

135 depletion by treatment of athymic rats with cobra venom factor (CVF) partially reverses this effect.

136 Transient complement inhibition with cobra venom factor (CVF) plus daily and continuing cyclo

137 Intraperitoneal injection of cobra venom factor (CVF) reduced C3 levels in the cornea

138 on of complement C3 or its inactivation with Cobra Venom Factor (CVF) result in impaired muscle regen

139 ell activation when it was preincubated with cobra venom factor (CVF) to deplete C3.

140 ing pulmonary xenograft dysfunction by using cobra venom factor (CVF) to deplete recipient complement

141 Administration of cobra venom factor (CVF), 1 day before and at the time o

142 xplored by intraperitoneal injection of 35 U cobra venom factor (CVF), 24 hours before antibody injec

143 s B or D but did bind to immobilized C3b and cobra venom factor (CVF), a C3b analogue.

144 A/2 as islet allograft recipients as well as cobra venom factor (CVF), a complement blocker, treatmen

145 l plasma, with or without heat inactivation, cobra venom factor (CVF), or lipopolysaccharide plus int

146 groups: no therapy, daily administration of cobra venom factor (CVF), or splenectomy plus daily CVF.

147 (MMF), anti-CD40L monoclonal antibody (mAb), cobra venom factor (CVF), pig hematopoietic growth facto

148 as generated in vivo by infusion of purified cobra venom factor (CVF), thymocyte apoptosis was signif

149 ction process was further investigated using cobra venom factor (CVF), which systemically depleted th

150 ties, but had normal susceptibilities to the cobra venom factor (CVF)-dependent convertase.

151 Median graft survival was 62 hr in cobra venom factor (CVF)-treated controls versus 108 hr

152 rats treated with cyclosporine (CsA) and/or cobra venom factor (CVF).

153 respond to intravenous injection of purified cobra venom factor (CVF).

154 vation and depletion of complement (C) using cobra venom factor (CVF).

155 (GV) with the induction of lung injury using cobra venom factor (CVF); b) PLV-CVF group, animals rece

156 ion was significantly (p < 0.001) delayed by cobra venom factor (CVF; 11 +/- 8 h in four of five case

157 1 microg/mouse), we depleted complement with cobra venom factor (CVF; 7 U/mouse, intravenously [i.v.]

158 A convertase assembled with cobra venom factor and Bb was decayed by DAF, albeit far

159 was inhibited by complement depletion using cobra venom factor and did not develop in C3(-/-) mice.

160 llowing systemic activation of complement by cobra venom factor and in the L-selectin-, P-selectin-,

161 eukostasis in mice systemically infused with cobra venom factor and intrapulmonary transendothelial m

162 term after transient complement depletion by cobra venom factor and T cell immunosuppression by cyclo

163 ic activation by the alternative pathway and cobra venom factor C3 convertases; and 4) for susceptibi

164 Cobra venom factor completely inhibited complement activ

165 This transient protection was abrogated by cobra venom factor depletion of complement from FcgammaR

166 C3(-/-) mice, and control mice injected with cobra venom factor developed pronounced corneal opacific

167 Treatment with cobra venom factor did not affect survival, confirming t

168 Depletion of circulating complement with cobra venom factor eliminated, as expected, injury recor

169 after elastase perfusion, mice treated with cobra venom factor exhibited a mean aortic diameter of 9

170 t C3 in the periphery through treatment with cobra venom factor had a seizure rate comparable to that

171 Injecting cobra venom factor into wild-type mice activated the AP

172 e LPS injection, activation of complement by cobra venom factor led to significant elevation of serum

173 In the cobra venom factor model, sCR1sLex and sCR1[desLHR-A]sLe

174 In monkeys that received neither cobra venom factor nor dextran sulfate (group 1), there

175 The effect of complement depletion with cobra venom factor on porcine bone marrow cell (BMC) eng

176 When compared with the cobra venom factor only group (GV-CVF 47 +/- 2 neutrophi

177 ated injury, either by the administration of cobra venom factor or soluble complement receptor I to t

178 diac transplants to survive long term (i.e., cobra venom factor plus cyclosporin A), inhibition of HO

179 nt depletion in CD55(-/-)CD59(-/-) mice with cobra venom factor prevented these effects.

180 Decomplementation by cobra venom factor resulted in impaired entry of hepatoc

181 Injection of cobra venom factor resulted in prolongation of cardiac x

182 pig hearts transplanted into rats treated by cobra venom factor to avoid the hyperacute rejection.

183 Treatment of mice with cobra venom factor to deplete complement had insignifica

184 block C4 and C3 split product binding or by cobra venom factor to trigger C3 consumption.

185 required for the protective effect of CRP as cobra venom factor treatment eliminated the effect of CR

186 ontributed to serum-induced dry eye disease, cobra venom factor was used to deplete complement activi

187 els, C3(-/-) mice and mice depleted of C3 by cobra venom factor were more susceptible to C. neoforman

188 type mice cotreated with the TLR ligands and cobra venom factor, a potent complement activator.

189 y experiments using serum with added EDTA or cobra venom factor, a protein that depletes C3.

190 DAF did not bind cobra venom factor, implying that Bb decay is accelerate

191 i-T-cell and natural killer cell antibodies, cobra venom factor, medronate-liposomes, and 4 Gy of who

192 swine kidney, maintenance therapy comprised cobra venom factor, mycophenolate mofetil, and an anti-C

193 T-cell depletion, complement depletion with cobra venom factor, mycophenolate mofetil, anti-CD154 mo

194 hymocyte globulin, complement depletion with cobra venom factor, short courses of anti-CD154 mAb ther

195 epletion with ATG, complement depletion with cobra venom factor, short courses of cyclosporine, mycop

196 howed that pretreatment of C57BL/6 mice with cobra venom factor, which depleted serum of complement a

197 ubstituted with the corresponding segment of cobra venom factor, Xenopus, or trout C3 (chimeric C3s)

198 determined the C5-cleaving properties of the cobra venom factor-dependent C5 convertase (CVF, Bb) mad

199 In contrast, zymosan- and cobra venom factor-induced AP complement activation, and

200 In the present study, we used cobra venom factor-induced decomplementation to investig

201 gammaR(-/-) mice, but not in C3(-/-) mice or cobra venom factor-treated mice.

202 rmal Lewis rats (complement-sufficient) with cobra venom factor-treated rats (complement-depleted).

203 rogenitor cells in marrow, were increased in cobra venom factor-treated recipients compared with simu

204 Sterne strain upon complement depletion with cobra venom factor.

205 en complement was depleted by treatment with cobra venom factor.

206 Lewis rats, using intravenously administered cobra venom factor.

207 complement components via pretreatment with cobra venom factor.

208 t participated in AP activation initiated by cobra venom factor.

209 shock due to acute complement activation by cobra venom factor.

210 pressure (PEEP) before the administration of cobra venom factor; d) CVF-PLV group, animals received p

211 ls received partial liquid ventilation after cobra venom factor; e) CVF-PEEP group, animals received

212 CVF-PEEP group, animals received PEEP after cobra venom factor; f) PLV only group, animals received

213 to the GP Ib thrombin-binding site or by the cobra venom metalloproteinase, mocarhagin, that hydrolyz

214 n Ib-IX-V complex, we utilized mocarhagin, a cobra venom metalloproteinase, to generate a fragment (H

215 Cardiotoxins (CTXs) from cobra venom show cytotoxicity toward several cell types.

216 ants of the group IA phospholipase A(2) from cobra venom were constructed and expressed in the methyl

217 act with CTX A3, a major component of Taiwan cobra venom, by use of affinity chromatography, circular

218 In Naja kaouthia cobra venom, we have earlier discovered a covalent dimer

219 Naja sputatrix (Malayan spitting cobra) venom contains 15% secretory PLA2 of its dry weig

220 hallenge were vaccines that contained the P1 COBRA VLP and either the X3 or X6 COBRA VLP vaccine.

221 In addition, the COBRA VLP vaccine is more effective than a homologous va

222 ned the P1 COBRA VLP and either the X3 or X6 COBRA VLP vaccine.

223 However, COBRA VLP-vaccinated nonhuman primates had reduced lung

224 Using isothermal calorimetry, COBRA was found to bind individual beta1-4-linked glucan

225 iction analysis (COBRA), and quantitative SB-COBRA was performed to study methylation of the TWIST2 p

226 ionally optimized broadly reactive antigens (COBRA) was used to design novel hemagglutinin (HA) vacci

227 y abundant CTX homologues from the Taiwanese cobra, we showed that slight variations on the spatial d

228 ogramming approach called loopless COBRA (ll-COBRA), which can be used to eliminate all steady-state

229 tionally optimized broadly reactive antigen (COBRA), which uses worldwide sequencing and surveillance

230 he combination of a well-established method, COBRA, which interrogates DNA methylation via the restri